GNLX

#3235
Genelux Corporation Common Stock
2.98
+4.56%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
2.98
2.98
Intervallo Annuale
1.99
8.54
Variazione giornaliera
+4.56%
Variazione Mensile
+2.05%
Variazione di 6 mesi
-19.46%
Variazione Annuale
-31.18%
Chiusura Precedente
2.85
Open
2.98
Bid
Ask
Low
2.98
High
2.98
Volume
7
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Notizie